Featured Research

from universities, journals, and other organizations

Daily doses of a new probiotic reduces 'bad' and total cholesterol

Date:
November 5, 2012
Source:
American Heart Association
Summary:
A new probiotic lowered LDL "bad" cholesterol and total cholesterol in patients with high cholesterol. The probiotic reduced molecules known as cholesterol ester saturated fatty acids, which have been tied to dangerous plaque buildup in the arteries.

Two daily doses of a probiotic lowered key cholesterol-bearing molecules in the blood as well as "bad" and total cholesterol, in a study presented at the American Heart Association's Scientific Sessions 2012.

Probiotics are live microorganisms (naturally occurring bacteria in the gut) thought to have beneficial effects; common sources are yogurt or dietary supplements.

In previous studies, a formulation of the bacteria, known as Lactobacillus reuteri NCIMB 30242, has lowered blood levels of LDL or "bad" cholesterol.

Such treatments are drawing increasing medical attention as researchers unravel how supplementing gut bacteria (microbiome) with probiotics can play a role in health and certain chronic diseases such as heart disease, said Mitchell L. Jones, M.D., Ph.D., lead author of the study and a research assistant in the Faculty of Medicine at McGill University in Montreal.

Researchers investigated whether the same probiotic could lower LDL and reduce blood levels of cholesterol esters -- molecules of cholesterol attached to fatty acids, a combination that accounts for most total blood cholesterol and has been tied to cardiovascular disease risk.

Researchers tracked cholesterol esters bound to saturated fat, which have been linked to dangerous arterial plaque buildup and occur at higher levels in coronary artery disease patients.

The study involved 127 adult patients with high cholesterol. About half the participants took L. reuteri NCIMB 30242 twice a day, while the rest were given placebo capsules.

Those taking the probiotic had LDL levels 11.6 percent lower than those on placebo after nine weeks. Furthermore, cholesterol esters were reduced by 6.3 percent and cholesterol ester saturated fatty acids by 8.8 percent, compared with the placebo group.

For the first time, research shows that the probiotic formulation can reduce cholesterol esters "and in particular reduce the cholesterol esters associated with 'bad' saturated fatty acids in the blood," said Jones, co-founder and chief science officer of Micropharma, the company that formulated the probiotic.

Furthermore, people taking the probiotic had total cholesterol reduced by 9.1 percent. HDL "good" cholesterol and blood triglycerides, a dangerous form of fat in the blood, were unchanged.

Scientists have proposed that Lactobacillus bacteria alone may impact cholesterol levels in several ways, including breaking apart molecules known as bile salts. L. reuteri NCIMB 30242 was fermented and formulated to optimize its effect on cholesterol and bile salts.

Based on correlations between LDL reduction and bile measurements in the gut, the study results suggest the probiotic broke up bile salts, leading to reduced cholesterol absorption in the gut and less LDL.

The probiotic worked at doses of just 200 milligrams a day, far lower than those for soluble fiber or other natural products used to reduce cholesterol.

"Most dietary cholesterol management products require consumption between 2 to 25 grams a day," Jones said.

Patients appear to tolerate the probiotic well and the probiotic strain L. reuteri has a long history of safe use, he said.

Because of the small number of patients involved in the study, researchers aren't sure if the impact of the probiotic differs between men and women or among ethnic groups.

Co-authors are Christopher J. Martoni, Ph.D. and Satya Prakash, Ph.D.

Micropharma funded the study and owns intellectual property rights for the formulation, which is expected to be on the U.S. market next year.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Daily doses of a new probiotic reduces 'bad' and total cholesterol." ScienceDaily. ScienceDaily, 5 November 2012. <www.sciencedaily.com/releases/2012/11/121105114620.htm>.
American Heart Association. (2012, November 5). Daily doses of a new probiotic reduces 'bad' and total cholesterol. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/11/121105114620.htm
American Heart Association. "Daily doses of a new probiotic reduces 'bad' and total cholesterol." ScienceDaily. www.sciencedaily.com/releases/2012/11/121105114620.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins